SpringWorks Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	54.75	54.9	11.23	-	-
Other Revenue	4.37	3.52	1.41	-	-
Revenue	59.12	58.42	12.63	-	-
Revenue Growth (YoY)	118.71%	362.50%	-	-	-
Gross Profit	59.12	58.42	12.63	-	-
Selling, General & Admin	4.35	5.63	19.84	8.38	5.97
Other Operating Expenses	0.51	0.26	1.55	1.64	4.09
Operating Expenses	21.37	22.08	27.38	12.9	12.28
Operating Income	37.76	36.34	-14.75	-12.9	-12.28
Interest Expense	-13.73	-12.95	-10.36	-0.7	-0.01
Interest & Investment Income	1.53	1.59	2.03	0.18	-
Other Non Operating Income (Expenses)	-0	-0	0	-0	0.17
Pretax Income	25.56	24.99	-23.08	-13.42	-12.12
Income Tax Expense	1.87	1.79	1.23	1.54	-
Net Income	23.69	23.21	-24.3	-14.96	-12.12
Net Income to Common	23.69	23.21	-24.3	-14.96	-12.12
Shares Outstanding (Basic)	93	86	86	86	86
Shares Outstanding (Diluted)	93	86	86	86	86
Shares Change (YoY)	7.88%	-	-	0.46%	-
EPS (Basic)	0.25	0.27	-0.28	-0.17	-0.14
EPS (Diluted)	0.25	0.27	-0.28	-0.17	-0.14
Free Cash Flow	31.48	13.42	-64.74	-11.4	-77.85
Free Cash Flow Per Share	0.34	0.15	-0.75	-0.13	-0.91
Gross Margin	100.00%	100.00%	100.00%	-	-
Operating Margin	63.86%	62.21%	-116.76%	-	-
Profit Margin	40.06%	39.72%	-192.39%	-	-
Free Cash Flow Margin	53.24%	22.97%	-512.47%	-	-
EBITDA	54.26	52.53	-8.77	-10.02	-10.06
EBITDA Margin	91.78%	89.91%	-69.39%	-	-
D&A For EBITDA	16.51	16.18	5.98	2.89	2.22
EBIT	37.76	36.34	-14.75	-12.9	-12.28
EBIT Margin	63.86%	62.21%	-116.76%	-	-
Effective Tax Rate	7.33%	7.14%	-	-	-
Revenue as Reported	59.12	58.42	12.63	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.